Growing evidence demonstrates that hepatitis B virus (HBV) integration and resulting insertional mutagenesis play an important role in cell growth or maintenance in hepatocellular carcinomas (HCCs). To determine if HBV integration occurs and affects cellular genes at such a stage of infection, we analysed viral-host junctions in chronic hepatitis tissues without HCC using PCR amplification with primers specific to human Alu-repeat and HBV. We obtained 42 independent viral-host junctions from six patients examined and identified chromosomal locations for 20 of the 42 junctions. In six clones, each integration apparently affected a single gene. These six candidate genes included one known tumor suppressor gene, three human homologs of drosophila genes that are critical for organ development, one putative oncogene and one recently found chemokine. Our data, together with previously reported HBV integrants in HCCs, suggested preferential HBV integration into chromosome 3 (P ¼ 0.022). Our virus-tagging approach provided (a) firm evidence of HBV integration in hepatocytes at an early stage of chronic infection and (b) revealed cellular genes possibly affected by HBV integration and potentially involved in early steps of the process leading to carcinogenesis.
Introduction
Epidemiologic data provide compelling evidence (Beasley et al., 1981; Yu et al., 2000) for a role of hepatitis B virus (HBV) in the development of hepatocellular carcinoma (HCC). HBV is thought to be one of the DNA tumor viruses, such as human papillomavirus (HPV) and Epstein-Barr virus (Nevins and Vogt, 1996) . HBV also shares with oncogenic retroviruses, a unique replication strategy through reverse transcription and a characteristic lifecycle that includes integration into the host genome (Bre´chot et al., 2000) . Despite extensive research, the precise mechanism whereby HBV infection contributes to hepatocarcinogenesis remains unclear. One complication is that human tumorigenesis is a multistep process and several viral mechanisms are possibly involved in each step, including cis-and transactivation of cellular genes by viral proteins, antiapoptotic action, induction of genomic instability and insertional mutagenesis (Nevins and Vogt, 1996) .
Several groups have independently reported HBV integration into the human telomerase reverse transcriptase (hTERT) gene in HCCs, as well as in hepatoma derived cell lines, proving that viral insertion activates hTERT expression and, possibly, maintenance of telomere length (Gozuacik et al., 2001; Horikawa and Barrett, 2001; Ferber et al., 2003a) . Insertional mutagenesis is an important mechanism common to both RNA and DNA virus-related oncogenesis. HPV integration into the hTERT gene has recently been reported (Ferber et al., 2003a) and others have reported clonal T-cell proliferation induced by integration of retrovirus into a human proto-oncogene (Hacein-Bey-Abina et al., 2003) . Furthermore, the integration of woodchuck hepatitis virus (WHV), an animal virus resembling HBV, often occurs in c-Myc or N-Myc genes. Direct transforming activity of WHV/Myc integrants is thought to lead to the development of animal HCCs (Hsu et al., 1988; Fourel et al., 1990) . Other reports describe genes with important roles in cell growth, such as retinoic acid receptor beta, cyclin A2, mevalonate kinase, sarco/endoplasmic reticulum calcium ATPase 1 and human minichromosome maintenance protein 8, undergoing deregulation by HBV insertion (for reviews, see Bre´chot et al., 2000; Paterlini-Bre´chot et al., 2003) . Cumulatively, these data strongly suggest that HBV insertional mutagenesis plays an important role in the human oncogenic process.
We previously reported that HBV integration occurs early during HBV infection, even after acute selflimiting hepatitis (Murakami et al., 2004) . Insertional mutagenesis may represent the first drastic genetic change during a long-lasting chronic viral carrier state, preceding the development of HCC by a few decades. Furthermore, we may be able to investigate HBV integration with little influence of genomic recombination and chromosomal losses or gains during the early phase of chronic infection.
There have been few investigations on HBV integration in chronic hepatitis tissues. A few reports have described host sequences adjacent to viral integration in chronic hepatitis (Yaginuma et al., 1987; Takada et al., 1990) . This paucity of data reflects limited human genome information as well as the lack of a suitable cloning method. We investigated integrated HBV-host junctions in liver tissues with chronic hepatitis B without HCC using HBV-Alu PCR (Minami et al., 1995) . We definitively identified host nucleotide sequences and chromosomal locations of HBV integration sites in chronic hepatitis tissues. This virus-tagging approach also identified genes possibly affected by HBV integrations at an early stage of chronic HBV infection. Some of these genes are aberrantly expressed depending on the hepatoma cell lines or HCC and surrounding nontumor tissues, suggesting a role in hepatocarcinogenesis. Our study also provided additional data on the chromosomal location of 20 HBV integrants. These data suggested preferential HBV integration on chromosome 3 in contrast to the previous contention that HBV integration is a random event (Tokino and Matsubara, 1991; Bre´chot et al., 2000) .
Results
Amplification and identification of viral-host junctions using HBV-Alu PCR and sequencing HBV-Alu PCR was performed using liver DNA from six patients with chronic hepatitis type B. Electrophoresis and subsequent hybridization of the PCR product with an HBV probe showed smearing signals in all six patients, suggesting multiple polyclonal HBV integrations in chronically HBV infected liver (Figure 1 ). The PCR products were inserted into a plasmid vector, a total of 160 clones that hybridized to an HBV probe were selected and their nucleic acid sequences were determined. Of these, 45 clones consisted of only HBV sequences but the remaining 115 clones contained viralhost junctions as intended. There were duplications of clones and, as a result, we obtained a total of 42 different viral-host junctions.
Chromosomal location of isolated viral-host junctions
A database homology search of host sequences on Genbank and UCSC revealed the chromosomal locations of viral-host junctions in 20 of 42 clones (Table 1) . We could not determine the chromosomal locations in the remaining 22 clones because they consisted of (a) extremely short cellular sequences or (b) only Alurepeats. These inserts contained an Alu primer sequence, unidentified short sequences, probably of host origin, adjacent HBV sequences and an HBV primer sequence. They presumably reflect viral integrations into Alurepeats or Alu-clusters.
HBV integration has been considered a random event and until now there has been no known chromosomal preference (Bre´chot et al., 2000) . Assuming that HBV integration is random and the chromosomal location of the viral-host junction depends on the size of each chromosome, we calculated the expected rate of HBV integration into each chromosome. We found three integrations in chromosome 3, a value two-fold higher than expected (1.34), but not statistically significant (P ¼ 0.15). Two other groups have recently reported consecutive analyses of HBV integration in HCCs and identified chromosomal localizations of 15 and 17 viralhost junctions (Gozuacik et al., 2001; Wang et al., 2004) . We performed statistical analysis using 52 viral-host junctions observed either in our laboratory or reported by others (Table 2 ). This analysis of data from three independent laboratories demonstrated that integrations in chromosome 3 were always higher than anticipated and the overall frequency (8/52) was statistically significant (P ¼ 0.022). There were no significant preferences in the other chromosomes.
Genes possibly affected by HBV integration
HBV integration can affect human gene expression by interrupting an open reading frame or by activating genomic transcription through viral enhancer activity (Nevins and Vogt, 1996; Bre´chot et al., 2000) . As the gene-poor regions greater than 500 kb are termed gene deserts (Nobrega et al., 2003) , we listed human genes located within 250 kb from or interrupted by HBV integration in the human genome databases.
Of the 20 integrants (Table 1) , 10 were found within intronic sequences of human genes with confirmed protein production (Genbank and/or UCSC) and two were situated in intronic sequences of genes with hypothetical protein products (Genbank). Three integrants were located within 'gene deserts' and no genes were apparently affected. In the other five clones, integrations occurred within 1.5 to 168 kb of the viral-host junctions. Therefore, we listed 27 cellular genes that might be affected by HBV integration from 17 of 20 clones (Table 1) . We observed HBV integrations close to multiple genes in eight of the clones, making it difficult to determine which genes are actually affected. We were also prudent in identifying HBV integrations situated upstream or downstream of the genes. Therefore, we chose genes whose open reading frames were interrupted by HBV integration. In six clones only a single gene was interrupted and there was apparently no other gene within 250 kb of the viral-host junction. These genes are candidates for genes affected by HBV and, as a result, they are possibly related to cell proliferation and survival. They include axis inhibitor 1 (AXIN1), homolog of bobby sox (BBX), AL713702 (hypothetical protein), catenin delta-2 (CTNND2), eyes absent 3 (EYA3), and homolog of odd Oz 2 (ODZ2). In order to characterize these six genes we examined their expression in hepatic cell lines and HCC tissues.
mRNA expression of cellular genes interrupted by HBV integration in cell lines, HCC and surrounding nontumorous tissues
With the exception of AXIN1 in human liver, the function and expression of the genes interrupted by HBV integration have not been fully investigated. Therefore, we semiquantitatively analysed mRNA expression of AXIN1, BBX, AL713702, CTNND2, EYA3, and ODZ2 in five human hepatoma-derived cell lines. These six genes were expressed, although not abundantly, in some or all of these cells ( Figure 2 ). It is noteworthy that three of these genes, ODZ2, CTNND2, and AL713702, showed marked differences in mRNA expression levels dependent on the cell lines. CTNND2 was not expressed in HLE or HLF cells, whereas AL713702 was not expressed in HLE, HLF, and HepG2 cells, even after two rounds of PCR using nested primers (data not shown). ODZ2 was scarcely expressed in HepG2 cells, but was abundant in HLE and HLF cells. In order to further characterize the expression patterns of these six genes, we analysed mRNA expression levels in seven human HCCs and corresponding nontumor tissues (Figure 3 ). EYA3 and BBX showed relatively homogenous expression levels in tumor and nontumor tissues. In contrast, AXIN1, ODZ2, and AL713702 demonstrated aberrant expression patterns. AXIN1 was not expressed in one tumor tissue and predominantly expressed in nontumor tissues in three of seven cases. In accordance with aberrant expression in hepatoma cell lines, ODZ2 was not expressed in one tumor tissue and showed lower expression in tumor tissues in four of seven cases. AL713702 was expressed in only one tumor tissue and three nontumor tissues. CTNND2 was expressed in all tissues and showed predominant expression in three tumor tissues, but showed lower expression in one nontumor tissue.
Discussion
We and others previously developed a PCR-based method to rapidly and specifically amplify HBV-host junctions (Minami et al., 1995) . This technique, coupled with the availability of the human genomic database, permitted the identification of as many HBV integration-related genes as have been reported in the past two decades (Bre´chot et al., 2000; Gozuacik et al., 2001; Paterlini-Bre´chot et al., 2003) . We here employed this HBV-Alu PCR because of its advantage in amplifying viral-host junctions that coexist with free viral sequences. Attempts to amplify viral-host junctions are often disrupted by free HBV-derived amplicons. This is particularly evident in chronic hepatitis tissues since free viral loads are usually greater in chronic hepatitis than in HCC (personal observation). In this study, 115 viralhost junctions and no more than 45 clones consisting only of HBV sequences were identified by screening 160 HBV-containing clones.
Our data, together with those of two other groups, have identified preferential HBV integrations into chromosome 3. We, as well as Gozuacik et al., employed an HBV-Alu PCR method to identify viral-host junctions, but Wang et al. used a conventional cloning procedure. Therefore, the identities of chromosomal preferences are independent of a cloning strategy bias. We also performed a database search for integrated HBV sequences in Genbank and identified 17 chromosomal locations in hepatoma-derived cell lines, HCCs, and chronic hepatitis tissues (data not shown). Integration in chromosome 3 was found in two of the 17 cases. Although these reports may contain intentional bias, the overall frequency of HBV integrations found in chromosome 3, including those in the database search, yielded a statistically significant ratio of 0.145 (P ¼ 0.016). We listed the integration sites in chromosome 3 that have been reported in the literature (Table 3 ). There were no common genes affected by HBV, but 3p14 and 3q25, which correspond to common fragile sites, FRA3B and FRA3D, respectively, may be preferential targets. It remains to be resolved whether or not this chromosomal preference is related to a viral integration process or to genomic recombination events during hepatocarcinogenesis or both. Viral integration events often show preferential or common sites. For example, WHV preferentially integrates into Myc oncogene families (Hsu et al., 1988; Fourel et al., 1990) , whereas HPV integration in cervical carcinoma frequently occurs near the c-Myc locus (Ferber et al., 2003b) and recurrently in the hTERT gene (Ferber et al., 2003a) . Retroviral tagging has identified several common genes affected by integration in mouse hematopoietic tumors (Shen et al., 2003) . As for HBV, common integration into hTERT has recently , 2003) . This observation, together with our finding of preferential HBV integration into chromosome 3, strongly suggests that HBV integration is not a random event and that there may be selective pressure. As HBV integration is not essential to its proliferative lifecycle, such selection would enhance viral survival in host cells. This mechanism could be related to the stimulation of host cell cycle, inhibition of cellular apoptosis, cell growth, and escape from the host immune system, leading to cellular proliferation in multistep tumorigenesis. It has also been reported that HPV integration occurs in chromosomal fragile sites (Thorland et al., 2003) . Common fragile sites are thought to be highly unstable and preferential sites for translocations, deletions, intrachromosomal gene amplification, and integration of plasmid DNA and tumor viruses, such as SV40 (Smith et al., 1998) . They are considered to be related to carcinogenesis owing to such genomic alterations. In our study, HBV integrations were found within common fragile sites in four of 20 (20%) clones (data not shown). However, most of the common fragile sites are not precisely mapped and additional studies are needed to define the relationship between integrated sequences and common fragile sites by molecular mapping.
All of the viral sequences that we identified were situated in either intronic or intergenic sequences, but not in the exons. Viral insertional mutagenesis can affect cellular gene expression by regulating enhancer and promoter activities or by altering the exon-intron junction, possibly forming chimeric transcripts or disrupting transcription. Human intergenic sequences can regulate transcription in genes residing as far away as 1 Mb (Lettice et al., 2002) . Retroviral integrations apparently affect expression of genes located over hundreds of kilobases from the integration site (Fourel et al., 1994) . Although it is difficult to definitively identify genes affected by viral insertion, we have listed genes within 250 kb of HBV integrations. Nevertheless, in six cases, integrations occurred within the gene coding regions and no other gene existed within 250 kb. Therefore, these genes are excellent targets for insertional mutagenesis.
Among these six genes, AXIN1 is well characterized in the mouse during development and in human cancer.
AXIN1 is a regulatory protein of a Wnt signaling pathway, which is crucial for the vertebral dorsalventral axis formation (Zeng et al., 1997) and is also related to colorectal and hepatic carcinogenesis in humans. Satoh et al. (2000) reported the simultaneous occurrence of AXIN1 mutation and the loss of heterozygosity in the responsible region in some human HCCs. On the basis of these data, AXIN1 is believed to function as a tumor suppressor.
EYA3, ODZ2, and BBX are human homolog of drosophila genes. EYA3 is a human homolog of the drosophila eyes absent gene, which is essential for eye development. In humans, EYA3 gene exhibits phosphatase activity and uses this enzymatic function to switch transcriptional activation of cofactors (Li et al., 2003) . ODZ2 is a human homolog of the drosophila tenascin major (ten-m) gene, an example of a pair-rule gene, that is, every odd-numbered body segment is deleted in ten-m mutant drosophila embryos. In mammals it encodes a transmembrane protein, putatively acting as a transcriptional regulator (Bagutti et al., 2003) . BBX is a human homolog of the drosophila bobby sox gene located in a flightless region and encoding a product with transcription factor activity (Maleszka et al., 1998) . All three human homologs of drosophila genes are essential to the developments of drosophila, but their functions in humans are still unknown.
CTNND2 is a component of the adherens junction complex and its overexpression alters cell morphology and motility (Lu et al., 1999) . It is expressed primarily in the central nervous system (Paffenholz and Franke, 1997), but it is also found in cancerous tissues in the prostate (Burger et al., 2002) .
AL713702 is a spliced mRNA with a hypothetical protein product. However, very recently, Tom Tang et al showed that AL713702 encodes a chemokine-like protein and they named it TAFA-1. TAFA-1 is almost exclusively expressed in the brain, but its function remains unresolved (Tom Tang et al., 2004) .
With the exception of AXIN1, the expression of these six genes in the liver, has not been studied extensively. Our study showed that all of these genes are expressed in hepatocytes at various levels and frequencies. Consistent with previous reports, AXIN1, a tumor suppressor protein, is markedly suppressed in three tumor tissues in comparison to corresponding nontumor tissues. Both HBV-related insertional mutagenesis M Minami et al EYA3 and BBX exhibit homogenous expression in cell lines and HCC tissues. Inasmuch as these two proteins are presumably transcriptional regulators and are expressed in the liver, additional study is needed to elucidate their roles in normal liver, chronic hepatitis and HCC tissues. ODZ2 and CTNND2 exhibit aberrant expression depending on the cell lines; for example, ODZ2 expression was higher in nontumorous tissues than in tumors in four of the seven cases, suggesting a tumor suppressive role. It is important to note that ODZ2 also colocalized with a tumor suppressor protein, PML, in the nucleus (Bagutti et al., 2003) . In contrast, CTNND2 expression was much higher in tumors than in nontumorous tissues in three of the seven cases. This expression pattern is consistent with a report on CTNND2 expression in prostate cancers (Burger et al., 2002) and suggests a tumor-promoting role of CTNND2. AL713702/TAFA-1 was expressed in two of five cell lines and in three of seven HCC cases, preferentially in nontumorous tissues. In summary, six genes interrupted by HBV integration included one known tumor suppressor gene, three human homologs of drosophila genes that are essential for development, one putative oncogene, and one newly found chemokine. Our observations suggest that HBVrelated insertional mutagenesis in chronic infected livers may be important in regulating cell growth and in the maintenance of viral proliferation in host cells. Interestingly, two genes, TAFA-1 and CTNND2, are exclusively expressed in the central nervous system in humans, but we identified their expression in HCCs, in surrounding cirrhotic liver and in hepatoma-derived cell lines. Their role in hepatocytes undergoing carcinogenic or inflammatory transition needs further investigation.
We listed 27 genes located within 250 kb of and possibly affected by HBV integrations, including several genes related to cell growth and survival. SRPK2 is a serine/threonine kinase expressed in mouse brain, lung, and testis. It phosphorylates the HBV core protein and is a possible molecular target for inhibiting HBV replication (Daub et al., 2002) . TERF2 is a key component of vertebrate telomeres and plays a protective role in cellular senescence (van Steensel et al., 1998) . OCIA is a novel protein found by screening cDNA libraries of ovarian cancer (Luo et al., 2001) . However, which gene is really affected is difficult to determine. In fact, we found that cells with HBV integration in the EYA3 (clone IW 2, Table 1 ) yielded 46 copies per 5000 cells whereas those with integration in the 11q21 (clone IW 3, Table 1 ) yielded 71 copies per 5000 cells (data not shown), suggesting that the extent of clonal expansion was comparable between these two integrated clones. It is also noteworthy that noncoding intergenic sequences sometimes regulate other gene expressions (Nobrega et al., 2003) . Sequences that appear unimportant at the moment may have critical roles in cell growth or viral proliferation. The accumulation of viral-tagging information will narrow the genomic region repeatedly affected and lead to the identity of affected genes and regions.
In conclusion, our results provide the first extensive description of HBV integration in chronic hepatitis tissues. These integrations are potentially susceptible to deregulate gene expression and lead to cell death or cell survival and uncontrolled growth. Our data have also suggested the utility of the viral-tagging approach to identify cellular genes related to cell growth and survival. Additional studies are needed to determine the function of the genes identified in this study and to elucidate the mechanisms regulating viral survival in host cells and leading to carcinogenesis.
Materials and methods

Liver tissues and DNA preparation
Liver tissues with chronic active hepatitis were obtained by needle biopsy from six patients diagnosed with chronic HBV infection. HCC and surrounding nontumor tissues were surgically obtained from seven patients, including four with HCV infection, two with HBV infection, and one with both HBV and HCV. These procedures were performed during the patients' clinical management. All of the patients provided written informed consent and the Ethics Committee of Kyoto Prefectural University of Medicine approved all aspects of the study. DNA was extracted using a G'NOME DNA isolation kit (BIO 101, Joshua Way, CA, USA) according to the manufacturer's instructions.
Cell lines and RNA preparation
Cell lines, HLE, HLF, HepG2, Huh7, and Li7, were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. RNA was extracted using TRIzol (Invitrogen) according to the manufacturer's instructions. RNA from normal liver was purchased from BD Biosciences (CA, USA).
Amplification of viral-host junction
Viral-host junctions were amplified by using primers specific to human Alu repeat and to HBV X region as previously reported (Murakami et al., 2004) . The amplified products were electrophoretically separated on 1.0% agarose gel, transferred to a Hybond-N þ nylon membrane (Amersham-Pharmacia) and the HBV-specific products were visualized by hybridization using a digoxigenin-labeled total HBV probe (DIG DNA Labeling and Detection kit, Roche Diagnostics).
Cloning and sequencing of PCR products
The PCR products were blunted by T4 DNA polymerase treatment and ligated into a plasmid pCAPs, using a PCR Cloning kit (Roche Diagnostics). Plasmid DNA was obtained by using a standard protocol. Insert DNA was separated on 1.0% agarose after enzyme digestion, blotted on a Nylon membrane and screened for HBV sequence by hybridization. HBV positive clones were sequenced by a 377 Prism DNA sequencer (Applied Biosystems Inc.).
Identification of chromosomal location of viral-host junction
The sequences were searched for homologies to HBV and pCAPs using the BLAST2 program on the NCBI homepage (http//www.ncbi.nih.gov/BLAST/). Sequences other than HBV and pCAPs were examined by the BLAST and MegaBLAST programs on the NCBI homepage and by the BLAT program on the UCSC genome browser (http//www.genome.ucsc.edu/cgi-bin/hgBlat, July 2003 freeze) to search for homologies to the human genome.
RT-PCR and quantification of RNA expression
In total, 1 mg of RNA from each cell line or liver tissue was transcribed into cDNA using an AMV reverse transcriptase and a random nine-mer primer. One fortieth of the cDNA was subjected to a semiquantitative 50 cycle RT-PCR using a LightCycler and a LightCycler FastStart DNA Master SYBR Green I kit (Roche Diagnostics) as per the Touch-Down PCR protocol. In order to deny possible amplification from pseudogenes, nontranscribed RNA was included and the amplified PCR product for each primer set was confirmed by direct sequencing. The specificity and quality of amplified PCR products were verified by electrophoresis on 1.5% agarose. The quantity of each cDNA was standardized using beta-actin; the detection limit was defined as 1.0 Â 10 2 copies to 1.0 Â 10 6 beta-actin expression level by using a LightCycler Control kit and a human beta-actin primer set (Roche Diagnostics). Each quantification was performed in duplicate. The primer sequences are listed (Table 4) .
Statistical analysis
A binomial test was employed to analyse the chromosomal frequency of HBV integration. Values of Po0.05 were considered to be statistically significant. 
